AU6220398A - Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity - Google Patents
Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activityInfo
- Publication number
- AU6220398A AU6220398A AU62203/98A AU6220398A AU6220398A AU 6220398 A AU6220398 A AU 6220398A AU 62203/98 A AU62203/98 A AU 62203/98A AU 6220398 A AU6220398 A AU 6220398A AU 6220398 A AU6220398 A AU 6220398A
- Authority
- AU
- Australia
- Prior art keywords
- scarring
- receptor
- mediated activity
- inhibiting interleukin
- reducing fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 title 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000037390 scarring Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9702944.1A GB9702944D0 (en) | 1997-02-13 | 1997-02-13 | Reducing fibrosis |
GB9702944 | 1997-02-13 | ||
PCT/GB1998/000319 WO1998036061A2 (en) | 1997-02-13 | 1998-02-13 | Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6220398A true AU6220398A (en) | 1998-09-08 |
Family
ID=10807559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU62203/98A Abandoned AU6220398A (en) | 1997-02-13 | 1998-02-13 | Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6220398A (en) |
GB (1) | GB9702944D0 (en) |
WO (1) | WO1998036061A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9818278D0 (en) * | 1998-08-22 | 1998-10-14 | Smith & Nephew | Compositions |
DK1129190T4 (en) | 1998-11-13 | 2017-04-03 | Immunex Corp | Human TSLP DNA and polypeptides |
ES2286128T3 (en) * | 2000-06-30 | 2007-12-01 | Zymogenetics, Inc. | ZCYTO21 PROTEIN INTERFERRED TYPE. |
DK1417231T3 (en) | 2001-07-23 | 2013-07-22 | Immunex Corp | MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN |
WO2004045507A2 (en) * | 2002-11-15 | 2004-06-03 | Centocor, Inc. | Anti-angiogenic uses of il-6 antagonists |
CA2539061A1 (en) * | 2003-09-22 | 2005-03-31 | Biovation Gmbh & Co. Kg | Use of an antagonist of il-6 for treating il-6-mediated diseases |
US20060171943A1 (en) * | 2005-02-01 | 2006-08-03 | Amgen Inc. | Compositions and methods of treating fibrotic disorders |
EP1941907B1 (en) | 2005-10-14 | 2016-03-23 | Fukuoka University | Inhibitor of transplanted islet dysfunction in islet transplantation |
KR101239051B1 (en) | 2005-10-21 | 2013-03-04 | 추가이 세이야쿠 가부시키가이샤 | Agents for treating cardiopathy |
AR057582A1 (en) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES |
CN101370521A (en) | 2006-01-27 | 2009-02-18 | 学校法人庆应义塾 | Remedy for disease associated with choroidal angiogenesis |
CA2648644C (en) | 2006-04-07 | 2016-01-05 | Osaka University | Muscle regeneration promoter |
MX2009001110A (en) | 2006-08-03 | 2009-05-11 | Vaccinex Inc | Anti-il-6 monoclonal antibodies and uses thereof. |
CN101646459B (en) | 2007-01-23 | 2014-02-12 | 国立大学法人信州大学 | Chronic rejection inhibitor |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
WO2009148148A1 (en) | 2008-06-05 | 2009-12-10 | 国立がんセンター総長が代表する日本国 | Neuroinvasion inhibitor |
HRP20221490T1 (en) | 2010-05-28 | 2023-02-03 | Chugai Seiyaku Kabushiki Kaisha | Antitumor t cell response enhancer |
WO2013106702A1 (en) | 2012-01-13 | 2013-07-18 | President And Fellows Of Harvard College | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
TW201829460A (en) | 2016-12-16 | 2018-08-16 | 新加坡商新加坡保健服務私人有限公司 | Il-11 antibodies |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
CA3070089A1 (en) * | 2017-07-19 | 2019-01-24 | Auckland Uniservices Limited | Cytokine modulation |
KR20200074160A (en) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | Pharmaceutical composition for inhibiting post-surgical adhesion containing anti-IL-6 receptor antibody |
EP3801525A4 (en) | 2018-06-08 | 2022-03-23 | The General Hospital Corporation | Inhibitors of prolyl-trna-synthetase |
JP2022518251A (en) | 2019-01-21 | 2022-03-14 | シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド | Treatment of hepatotoxicity |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8910891A (en) * | 1990-11-20 | 1992-06-11 | National Heart & Lung Institute, The | Treatment of lung diseases |
JP3525221B2 (en) * | 1993-02-17 | 2004-05-10 | 味の素株式会社 | Immunosuppressants |
WO1994025036A1 (en) * | 1993-04-30 | 1994-11-10 | Chugai Seiyaku Kabushiki Kaisha | Expression inhibitor containing antisense oligonucleotide derivative against human interleukin-6 receptor |
RU2147442C1 (en) * | 1994-10-21 | 2000-04-20 | Кисимото Тадамицу | Pharmaceutical composition for prophylaxis or treatment of diseases caused by il-6 formation |
IT1274782B (en) * | 1994-12-14 | 1997-07-24 | Angeletti P Ist Richerche Bio | METHOD FOR SELECTING SUPERAGONISTS, ANTAGONISTS AND SUPERANTAGONISTS OF HORMONES OF WHICH RECEPTOR COMPLEX IS PART OF GP 130 |
AU3193097A (en) * | 1996-06-20 | 1998-01-07 | Koster, Henk W. | Il-6 and il-6-receptor derived peptides having il-6 antagonistic or agonistic activity |
-
1997
- 1997-02-13 GB GBGB9702944.1A patent/GB9702944D0/en active Pending
-
1998
- 1998-02-13 WO PCT/GB1998/000319 patent/WO1998036061A2/en active Application Filing
- 1998-02-13 AU AU62203/98A patent/AU6220398A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GB9702944D0 (en) | 1997-04-02 |
WO1998036061A2 (en) | 1998-08-20 |
WO1998036061A3 (en) | 1998-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6220398A (en) | Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity | |
AU6244098A (en) | Distributed game | |
AU3741699A (en) | Personal location system | |
AU4943200A (en) | Modified cytokine | |
AU4723296A (en) | Compositions having depigmenting activity, and uses thereof | |
AU1024899A (en) | Cytokines having neurotrophic activity | |
AU3206697A (en) | Ribozyme-mediated gene replacement | |
AU5203698A (en) | Fluid-treatment assemblies | |
AU2321397A (en) | Construction block structure | |
EP0903415A3 (en) | Structure expansée | |
AU8165298A (en) | Cardiotrophin-like cytokine | |
AU7474998A (en) | Haloisoquinoline carboxamide | |
AU7020398A (en) | Personal communications system | |
AU9367198A (en) | Enzymatic modification | |
AU1365499A (en) | Pre-orienting nozzle | |
AU6673898A (en) | Factor x variant | |
AU3702399A (en) | Catalytically active structure | |
AU6230398A (en) | Thrombolytic agent | |
AU1873499A (en) | Semi-submersible structure | |
AU8736698A (en) | Shale-stabilizing additives | |
AU7308300A (en) | Agents for reducing cholesterol-uptake and liquid-uptake | |
AU7162898A (en) | Regioisomeric benzothiopyranopyridines having antitumor activity | |
AU8808098A (en) | Bis-acridinecarboxamides having antitumor activity | |
AU7226598A (en) | Stay | |
AU4414699A (en) | Printhead attachment structure and method |